Cargando…
Bevacizumab or laser for aggressive posterior retinopathy of prematurity
PURPOSE: The purpose of this study was to report the rate of reactivation and structural outcome, after the laser or bevacizumab treatment for aggressive posterior retinopathy of prematurity (APROP). METHODS: Retrospective chart review was conducted on consecutive infants with APROP treated with (1)...
Autores principales: | Blair, Michael, Gonzalez, Jose Maria Garcia, Snyder, Laura, Schechet, Sidney, Greenwald, Mark, Shapiro, Michael, Rodriguez, Sarah Hilkert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302568/ https://www.ncbi.nlm.nih.gov/pubmed/30637196 http://dx.doi.org/10.4103/tjo.tjo_69_18 |
Ejemplares similares
-
Reply to comment on: “Advantages of bevacizumab for aggressive posterior retinopathy of prematurity”
por: Schechet, Sidney A., et al.
Publicado: (2019) -
Comment on “bevacizumab or laser for aggressive posterior retinopathy of prematurity”
por: Samanta, Ramanuj
Publicado: (2019) -
Favorable outcomes of adequate laser photocoagulation and salvage bevacizumab treatment for aggressive posterior retinopathy of prematurity
por: Fukushima, Yoko, et al.
Publicado: (2018) -
Aggressive Posterior Retinopathy of Prematurity: Long-Term Outcomes Following Intravitreal Bevacizumab
por: Naravane, Ameay V., et al.
Publicado: (2022) -
Regression Rates Following the Treatment of Aggressive Posterior Retinopathy of Prematurity with Bevacizumab Versus Laser: 8-Year Retrospective Analysis
por: Nicoară, Simona D., et al.
Publicado: (2016)